目的 :探讨胺碘酮联合联合阿托伐他汀治疗非缺血性心衰伴恶性心律失常的疗效及安全性分析。方法:本研究选取了180例非缺血性心衰伴恶性心律失常患者,胺碘酮组(88例)给予胺碘酮,联合用药组(92例)给予胺碘酮和阿托伐他汀,观察并记录两组患者治疗后的疗效,肿瘤坏死因子(TNF-α),白细胞介素(IL-6),高敏C反应蛋白(hs-CRP)等炎性因子,随访资料,评价胺碘酮与阿托伐他汀治疗非缺血性心衰伴恶性心律失常的疗效。结果:治疗后联合用药组有效率明显高于胺碘酮组,治疗前,两组TNF-α,IL-6,hs-CRP水平相比,差异没有统计学意义。治疗后,两组TNF-α,IL-6,hs-CRP水平均明显降低,且联合用药组上述指标均明显低于胺碘酮组;治疗后,联合用药组患者生理功能,生理职能,躯体疼痛,总体健康评分均明显高于胺碘酮组;随访6个月期间,两组在频发室性早搏、室性阵发性心动过速、心功能恶化上相比,差异没有统计学意义。联合用药组死亡率明显低于胺碘酮组。结论 :胺碘酮联合阿托伐他汀对非缺血性心衰伴恶性心律失常具有较好的治疗作用,能减轻炎症反应,提高患者生活质量,降低患者病死率,值得临床推广使用。 Objective: To investigate the efficacy and safety of amiodarone combined with atorvastatin in the treatment of non-ischemic heart failure with malignant arrhythmia. Methods: A total of 180 patients with non-ischemic heart failure and malignant arrhythmia were enrolled in this study. Amiodarone was given in the amiodarone group (88 patients) and amiodarone and atorvastatin in the combination group (92 patients) The curative effect, the inflammatory factors such as tumor necrosis factor (TNF-α), interleukin (IL-6) and high-sensitivity C-reactive protein (hs-CRP) were observed and recorded after follow- And atorvastatin in the treatment of non-ischemic heart failure with malignant arrhythmias. Results: After treatment, the effective rate of combined treatment group was significantly higher than that of amiodarone group. There was no significant difference in the levels of TNF-α, IL-6 and hs-CRP between the two groups before treatment. After treatment, the levels of TNF-α, IL-6 and hs-CRP in both groups were significantly decreased, and the above indexes in combination group were significantly lower than those in amiodarone group. After treatment, the combination of physical function, physiological function, Pain and overall health score were significantly higher than those in the amiodarone group. There was no significant difference between the two groups in frequency of premature ventricular contractions, ventricular paroxysmal tachycardia and cardiac dysfunction over a 6-month follow-up . The combination group mortality was significantly lower than the amiodarone group. Conclusion: Amiodarone combined with atorvastatin has a good therapeutic effect on non-ischemic heart failure with malignant arrhythmia, which can reduce the inflammatory reaction, improve the quality of life and reduce the mortality of patients, which is worthy of clinical promotion.